Nordic Nanovector ASA (NANO):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Nordic Nanovector ASA (NANO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8240
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ノルウェー
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Nordic Nanovector ASA (Nordic Nanovector), formerly Nordic Nanovector AS is a developer and commercializer of antibody radionuclide conjugates for the treatment of haematological cancers. The company’s lead product candidate includes Betalutin, an antibody radionuclide conjugate developed for the treatment of non-Hodgkin Lymphoma, a life-threatening blood cancer. Its Betalutin consists of tumour-specific antibody HH1, which targets CD37 antigen on the surface of NHL cells. Nordic Nanovector develops products for the treatment of multiple cancer indications by utilizing innovative therapy programmes and patented technologies. The company evaluates chimeric anti-CD37 antibodies with different payloads for the treatment of both types of leukaemia. It operates in Norway, Switzerland and the UK. Nordic Nanovector is headquartered in Oslo, Norway.

Nordic Nanovector ASA (NANO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Nordic Nanovector ASA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Nordic Nanovector Raises USD8.34 Million In A Financing Round 11
Nordic Nanovector Raises US$10 Million In Series A Financing 12
Nordic Nanovector Raises US$2.4 Million In Venture Financing 13
Partnerships 14
Nordic Nanovector Enters into Research Agreement with Heidelberg Pharma 14
Nordic Nanovector Enters into Partnership with LegoChem Biosciences 15
Nordic Nanovector Enters into Agreement with Areva Med 16
Nordic Nanovector Enters into R&D Agreement with Paul Scherrer Institute 17
Nordic Nanovector Enters into Co-Development Agreement with Affibody 18
Equity Offering 19
Nordic Nanovector Raises USD1.2 Million in Rights Offering of Shares 19
Nordic Nanovector Raises USD59 Million in Private Placement of Shares 20
Nordic Nanovector Completes IPO 21
Nordic Nanovector Raises USD7.7 Million in Rights Offering of Shares 23
Nordic Nanovector Raises USD41.7 Million in Private Placement of Shares 24
Nordic Nanovector ASA – Key Competitors 25
Nordic Nanovector ASA – Key Employees 26
Nordic Nanovector ASA – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Financial Announcements 28
Aug 22, 2018: Nordic Nanovector: results for the second quarter and first half 2018 28
May 30, 2018: Nordic Nanovector – Results for the First Quarter 2018 31
Feb 27, 2018: Nordic Nanovector- Results for the Fourth Quarter and Full Year 2017: Solid Performance Through 2017, Moving Forward With Pivotal Trial 32
Nov 22, 2017: Nordic Nanovector – Results for the Third Quarter 2017 34
Aug 23, 2017: Nordic Nanovector – Results for Second Quarter and First Half Year 2017 36
May 24, 2017: Nordic Nanovector: Results for First Quarter 2017 38
Feb 28, 2017: Nordic Nanovector: Results for Fourth Quarter and Full Year 2016 39
Corporate Communications 40
Jun 01, 2018: Nordic Nanovector Strengthens Management Team With Appointment of Maureen Deehan, PhD, as Head of Corporate Development and Strategy 40
May 30, 2018: Nordic Nanovector Names Rainer Boehm As Board Director 41
Apr 20, 2018: Nordic Nanovector Appoints Tone Kvale As Interim Chief Executive Officer 42
Apr 04, 2018: Nordic Nanovector announces that Luigi Costa will step down as Chief Executive Officer 43
Product News 44
01/04/2017: Nordic Nanovector to Present at Biotech Showcase 2017 44
Clinical Trials 45
Mar 15, 2018: Nordic Nanovector to Present Preclinical Data Highlighting the Anti-tumour Effect of Humalutin in Three Lymphoma Models at AACR 2018 45
Mar 17, 2017: Nordic Nanovector announces first patient dosed in Phase 1 study of Betalutin in diffuse large B-cell lymphoma, an aggressive form of NHL 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Nordic Nanovector ASA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Nordic Nanovector ASA, Deals By Therapy Area, 2012 to YTD 2018 9
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Nordic Nanovector Raises USD8.34 Million In A Financing Round 11
Nordic Nanovector Raises US$10 Million In Series A Financing 12
Nordic Nanovector Raises US$2.4 Million In Venture Financing 13
Nordic Nanovector Enters into Research Agreement with Heidelberg Pharma 14
Nordic Nanovector Enters into Partnership with LegoChem Biosciences 15
Nordic Nanovector Enters into Agreement with Areva Med 16
Nordic Nanovector Enters into R&D Agreement with Paul Scherrer Institute 17
Nordic Nanovector Enters into Co-Development Agreement with Affibody 18
Nordic Nanovector Raises USD1.2 Million in Rights Offering of Shares 19
Nordic Nanovector Raises USD59 Million in Private Placement of Shares 20
Nordic Nanovector Completes IPO 21
Nordic Nanovector Raises USD7.7 Million in Rights Offering of Shares 23
Nordic Nanovector Raises USD41.7 Million in Private Placement of Shares 24
Nordic Nanovector ASA, Key Competitors 25
Nordic Nanovector ASA, Key Employees 26
Nordic Nanovector ASA, Subsidiaries 27

List of Figures
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Nordic Nanovector ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Nordic Nanovector ASA (NANO):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Isagenix International LLC:企業の戦略的SWOT分析
    Isagenix International LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Aozora Bank Ltd:企業の戦略・SWOT・財務情報
    Aozora Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary Aozora Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • genedrive plc (GDR)-製薬・医療分野:企業M&A・提携分析
    Summary genedrive plc (genedrive), formerly Epistem Holdings plc is a molecular diagnostics company. The company focuses on the development and commercialization of simple to use “point of need” system or point of care diagnostics platform for the diagnosis of infectious diseases and use in patient …
  • The McClatchy Company (MNI):企業の財務・戦略的SWOT分析
    The McClatchy Company (MNI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Auris Medical Holding Ltd (EARS):企業の財務・戦略的SWOT分析
    Auris Medical Holding Ltd (EARS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Yellowstone Valley Electric Cooperative, Inc.:企業の戦略的SWOT分析
    Yellowstone Valley Electric Cooperative, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors …
  • Nevada Gold & Casinos, Inc.:企業の戦略・SWOT・財務情報
    Nevada Gold & Casinos, Inc. - Strategy, SWOT and Corporate Finance Report Summary Nevada Gold & Casinos, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Bunge Ltd (BG):企業の財務・戦略的SWOT分析
    Bunge Ltd (BG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Bayer AG (BAYN):医療機器:M&Aディール及び事業提携情報
    Summary Bayer AG (Bayer) carries out the research, development, production and commercialization of products for human and animal health care, and agriculture. It provides medicines for cardiovascular diseases, women’s health, cancer, hematology, ophthalmology and other indications. The company's pr …
  • Amgen, Inc.:企業の戦略・SWOT・財務情報
    Amgen, Inc. - Strategy, SWOT and Corporate Finance Report Summary Amgen, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Origin Energy Limited:企業の戦略・SWOT・財務情報
    Origin Energy Limited - Strategy, SWOT and Corporate Finance Report Summary Origin Energy Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • United Technologies Corporation:戦略・SWOT・企業財務分析
    United Technologies Corporation - Strategy, SWOT and Corporate Finance Report Summary United Technologies Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Sharjah Electricity & Water Authority:企業の戦略的SWOT分析
    Sharjah Electricity & Water Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and maj …
  • Gerresheimer AG:戦略・SWOT・企業財務分析
    Gerresheimer AG - Strategy, SWOT and Corporate Finance Report Summary Gerresheimer AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Electromagnetic Geoservices ASA (EMGS):企業の財務・戦略的SWOT分析
    Summary Electromagnetic Geoservices ASA (EMGS) is an oil and gas service provider that explores workflow working with seismic, petrophysical and geologic data. The company gathers controlled source electromagnetic data and conduct modeling, integration, interpretation. Its technology finds applicati …
  • China Oilfield Services Ltd (2883):石油・ガス:M&Aディール及び事業提携情報
    Summary China Oilfield Services Ltd (COSL) is an integrated oilfield services company. Its services cover each phase of offshore oil and gas exploration, development and production. Its products portfolio includes logging and perforation equipment, oilfield chemicals, well completion tools, sand con …
  • Exagen Diagnostics Inc:医療機器:M&Aディール及び事業提携情報
    Summary Exagen Diagnostics Inc (Exagen) is a medical device company that offers diagnostic tools. The company provides clinical tools for diagnosis, monitoring and prognosis of autoimmune connective tissue disease. Its products are used for therapeutic drug monitoring of hydroxychloroquine in whole …
  • SCHOTT AG:企業の戦略・SWOT・財務情報
    SCHOTT AG - Strategy, SWOT and Corporate Finance Report Summary SCHOTT AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Mazda Motor Corp (7261):企業の財務・戦略的SWOT分析
    Mazda Motor Corp (7261) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • ICON Plc (ICLR):製薬・医療:M&Aディール及び事業提携情報
    Summary ICON plc (ICON) is a contract research organization (CRO) that provides outsourced development services to the biotechnology, pharmaceutical and medical device industries worldwide. It provides a range of specialized services that span the entire lifecycle of product development. The company …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆